Prolactin level in systemic lupus erythematosus patients

Zahra Zakeri; Behzad Narouie; Abdosamad Shikhzadeh; Afshin Nejati-afkham; Mohammad Ghasemi-rad

Journal of Kermanshah University of Medical Sciences

Peer-reviewed Medical Quarterly

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards and Committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Reviewer and AE Registration Form Contact Us Support

Authors Guide Submit Manuscript

Prolactin level in systemic lupus erythematosus patients

Author(s):

Zahra Zakeri¹,

Behzad Narouie^2,*,

Abdosamad Shikhzadeh²,

Afshin Nejati-afkham³,

Mohammad Ghasemi-rad⁴

1Dept. of Rheumatology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

2Clinical Research Development Center, Zahedan University of Medical Sciences, Zahedan, Iran

3Dept. of Internal Medicine, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

4School of Medicine, Urmia University of Medical Sciences, Urmia, Iran

Journal of Kermanshah University of Medical Sciences:Vol. 14, issue 2; e79513

Published online:Sep 19, 2010

Article type:Research Article

Received:Aug 02, 2009

Accepted:Dec 29, 2009

How to Cite:Zahra ZakeriBehzad NarouieAbdosamad ShikhzadehAfshin Nejati-afkhamMohammad Ghasemi-radProlactin level in systemic lupus erythematosus patients.J Kermanshah Univ Med Sci.14(2):e79513.

Abstract

Background: Recent accumulated evidence suggests that prolactin (PRL) is an important immunomodulator and plays an important role in the pathogenesis of systemic lupus erythematosus (SLE). The current study aimed to compare hyperprolactinemia frequency and evaluate its possible association with lupus activity in SLE patients in zahedan.

Methods: In a case-control study we determined serum prolactin (PRL) level in 40 female patients with SLE (active=12 and non active=28) and in 40 normal healthy female subjects (NHS). Clinical and serologic activity of disease was assessed for each patient using the SLEDAI score. Anti ds DNA, C3, C4, CH50 were determined using ELISA method.

Results: Elevated serum concentrations of PRL (> 25 μg/l) were found in seven patients and two NHS group, but there was no significant difference between lupus and control groups (p=0.07). Hyperprolactinemia SLE patients in active lupus group (SLEDAI > 10) and inactive group were 6 and 1 respectively and there was significant difference between these two groups (p=0.001).

Conclusion: Hyperprolactinemia was frequently detected in patients with active SLE. The findings suggest significant correlation between Hyperprolactinemia and lupus activity, which need further investigation including large sample size SLE subject and control group.

Keywords

hyperprolactinemia

systemic lupus erythematosus

disease activity

Fulltext

References

1.
The references of this article is available on PDF.

comments